Stocks/MTRI/News

MTRI stock news today

Headlines, SEC filings, press releases, analyst ratings and earnings for MTRI from the last 90 days. Updated Nov 20, 2026.

Analyst: 3

Friday, November 13, 2026

AnalystBenzinga

Wedbush starts Mentari Therapeutics coverage with Outperform rating and $33 price target

Wedbush began covering Mentari Therapeutics with an Outperform rating. The firm set a $33 price target on the shares.

Tuesday, November 10, 2026

AnalystBenzinga

Jefferies starts Mentari Therapeutics coverage with Buy rating and $30 price target

Jefferies began covering Mentari Therapeutics and gave the shares a Buy rating. The firm set a $30 price target on the stock.

AnalystBenzinga

Stifel starts Mentari Therapeutics coverage with Buy rating and $30 price target

Stifel began covering Mentari Therapeutics and rated the shares Buy. The firm set a $30 price target on the stock.

Frequently asked questions

What is the latest news on MTRI?

Nov 13, 2026: Wedbush starts Mentari Therapeutics coverage with Outperform rating and $33 price target (Benzinga) · Nov 10, 2026: Jefferies starts Mentari Therapeutics coverage with Buy rating and $30 price target (Benzinga) · Nov 10, 2026: Stifel starts Mentari Therapeutics coverage with Buy rating and $30 price target (Benzinga)

Get MTRI news as it happens

Every headline, SEC filing and analyst action for MTRI on your live chart, with important news marked and alerts when it matters.

Try SEPT Free

More MTRI Research

MTRI FundamentalsMTRI AnalysisMTRI SEC FilingsSEPT Academy
Share:XRedditFacebookLinkedIn
© SEPT Investing. Headlines link to their original sources. Not financial advice. Trading involves risk.